Hemozoin Adjuvant Enhancing Vaccine Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants do not effectively potentiate the in vivo effects of allergen, infection, mucosal, and tumor vaccines, particularly in activating immune responses against pathogens and reducing allergic and infectious diseases.
Innovation Solution
A vaccine adjuvant composition comprising hemozoin or β-hematin, used in combination with allergen, infection, mucosal, or tumor vaccines, activates immune cells and induces specific antibody production, enhancing immune responses and reducing disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants are used with vaccines, then immune response is enhanced, but the adjuvant effect is insufficient for allergen, infection, mucosal, and tumor vaccines
Solution Approach 1:
The patent applies hemozoin or β-hematin as a universal adjuvant that can be used with multiple types of vaccines including allergen vaccines, infection vaccines, mucosal vaccines, and tumor vaccines. This single adjuvant material provides enhanced immune responses across different vaccine formulations, eliminating the need for different adjuvants for different vaccine types.
2Reliability
If hemozoin or β-hematin is used as adjuvant, then antibody production and immune activation are significantly enhanced, but the mechanism for mucosal immunity induction needs to be established
Solution Approach 1:
The patent identifies hemozoin and β-hematin as intermediary substances that activate dendritic cells and antigen-presenting cells, which then mediate the induction of mucosal immunity. These adjuvants serve as mediators between the vaccine antigen and the immune system, triggering dendritic cell activation that leads to enhanced antibody production and mucosal IgA induction.
3Productivity
If vaccine adjuvant composition is used, then in vivo vaccine effects are potentiated, but the optimal concentration range needs to be determined
Solution Approach 1:
The patent specifies an optimal concentration range of 5 μM to 2 mM for hemozoin or β-hematin in the vaccine adjuvant composition. By defining this parameter range, the patent enables manufacturers to achieve consistent and potentiated vaccine effects while maintaining precise control over adjuvant concentration during formulation and production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of hemozoin or β-hematin as an adjuvant significantly elevates antibody titers against pathogens, induces mucosal IgA production, and reduces tumor size, effectively preventing or treating allergic, infectious, and tumor-related diseases.
Implementation Method 1
hemozoin acts as a ligand of Toll-like receptor 9 (TR9). It is reported that the Toll-like receptor 9 is involved in the innate immune response to various pathogens including Plasmodium. In other words, immune system is activated in a MyD88-dependent manner when Toll-like receptor 9 recognizes a ligand.
Data Source
AI summary
The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine.